Montefiore Medical Center (Moses Campus)
The Bronx, NY
Accepting patients
Venetoclax in Combination With ASTX727
Venetoclax in Combination With ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
Accepting patients
Danvatirsen Plus Venetoclax
A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
- Antisense Oligonucleotide (ASO)
- BCL-2 Inhibitor
- Phase 1
Accepting patients
AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
- Monoclonal Antibody
- CD47
- Closed Label (Masked)
- Placebo
- Randomization
- Phase 2
Accepting patients
Low Dose Weekly Decitabine/Venetoclax
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
Accepting patients
PedAL Screening
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
- Phase 1/2
Accepting patients
MyeloMATCH Master Protocol
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
- Genetic Sequencing
- Phase 2
Accepting patients
Tetrahydrouridine + Decitabine
Phase 1 Study of Oral Tetrahydrouridine-Decitabine to Treat Relapsed or Refractory Myelodysplastic Syndromes
- Cytidine Deaminase Inhibitor
- Phase 1
Accepting patients
SX-682
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- CXCR1 Inhibitor
- CXCR2 Inhibitor
- Phase 1
- Has results